Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nazartinib + Capmatinib in EGFR-Mutated NSCLC
NCT02335944Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2015
- Primary completion
- Nov 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
A Phase 2 trial of nazartinib, capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jan 2015; status: terminated.
02
Drugs
nazartinibcapmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02335944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335944.